Corporate Profile
Company name | AskAt Inc. |
---|---|
Locations |
|
Establishment | January 7, 2013 |
Capital | 87,000,000 yen |
President | Akihiro Furuta |
History
January 2013 | Is launched with capital of 1,000,000 yen as a wholly owned subsidiary of RaQualia Inc. Acquires the following compounds as intellectual property: ・EP4 antagonist / AAT-007, AAT-008 ・5-HT4 partial agonist / AAT-009 ・COX-2 inhibitor / AAT-076 President Shinichi Koizumi |
---|---|
June 2013 | Acquires management rights from RaQualia Inc. |
September 2014 | Relocation of head office to Showa-ku, Nagoya |
March 2015 | Akihiro Furuta becomes president Becomes fully independent of RaQualia |
June 2015 | Issues new shares to third parties (capital 9,750,000 yen) |
August 2015 | Issues new shares to third parties (capital 17,000,000 yen) |
November 2015 | Acquires CB2 agonist intellectual property from RaQualia Inc. Issues new shares to third parties (capital 32,000,000 yen) |
January 2016 | Concludes license agreement with RMX for AAT-076 and AAT-007 in China. Issues new shares to third parties (capital 37,000,000 yen) |
March 2016 | Issues new shares to third parties (capital 62,000,000 yen) |
December 2016 | Concludes license agreement with Ningbo Tai Kang for AAT-007 in China. |
May 2017 | Issues new shares to third parties (capital 87,000,000 yen) |
December 2017 | Concludes worldwide license agreement (excluding China and Taiwan) with Arrys Therapeutics for AAT-007 and AAT-008 Transition to a company with board of directors / company auditor |
February 2018 | Concludes license agreement with NewBay Medical Technology for AAT-008 in China and Taiwan Concludes worldwide license agreement with Aratana Therapeutics for AAT-008 in animal health |
March 2018 | Transition to a company with audit and supervisory committee |
August 2018 | Relocation of head office to Nakamura-ku, Nagoya |